Purchase Order HHSD2002016M88776P

Award Date 2/9/16
Potential Completion Date 2/12/16
Potential Value $96K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Atlanta, GA 30329, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Other Statutory Authority
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc. for the purchase of DNA prep library and sequencing kits compatible with Illumina's MiSeq, MiniSeq, and NextSeq instruments. The CDC is the sole source for these Illumina products, as Illumina is the only manufacturer and does not have any authorized resellers in the United States. The total ceiling value of the purchase order is $248,576.11, with a period of performance...
The Centers for Disease Control and Prevention awarded a $1,852.50 firm fixed price purchase order to Illumina, Inc. for an Illumina NextSeq Sequencer. As the sole manufacturer of this proprietary sequencing instrument, Illumina will deliver one NextSeq Sequencer to support genomic analysis activities at the CDC's Pittsburgh location. No set-aside provision was applied to this acquisition of an Illumina sequencing system, which will aid the CDC in disease detection, surveillance, and research...
Illumina, Inc. has been awarded a $97,020 firm fixed price purchase order by the Centers for Disease Control and Prevention (CDC) for an Illumina MiSeq sequencing system. The place of performance is in San Diego, California. No set-aside provision was applied to this acquisition. The CDC is a component of the Department of Health and Human Services that conducts research and provides guidance related to public health issues such as infectious diseases. This purchase will support the CDC's...
This is a $94,050.00 firm fixed price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a manufacturer of sequencing and analysis instruments and reagents. The award is for an Illumina MiSeq sequencing system and does not have a set-aside designation. Illumina has a history of providing sequencing equipment and services to support research and diagnostics across various federal agencies, including the National Institutes of Health, Department of...
This is a firm fixed price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a for-profit manufacturer of genetic sequencing instruments and reagents. The contract is for the provision of an Illumina MiSeq genomic sequencing system, with a ceiling value of $135,435.37 and a performance period ending on November 30, 2015. The order does not have a set-aside designation. Illumina has previously received prime federal contract awards from agencies...
The Department of Health and Human Services Centers for Disease Control and Prevention (CDC) awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of genomic sequencing systems and reagents, for the procurement of a NEXTSEQ 1000 SEQUENCING SYSTEM. The total potential value of the award is $205,800.00 with a completion date of August 23, 2021. Illumina has a history of providing sequencing equipment, consumables, and services to federal agencies such as the National...
This is a firm fixed price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a manufacturer of genetic sequencing systems and reagents. The contract is for MiSeq and MiniSeq sequencing systems and reagents, with a ceiling value of $132,300.66 and a period of performance through August 31, 2016. This contract does not have a set-aside designation. Illumina has a history of providing sequencing instruments, reagents, and related services to federal...
This is a federal contract award from the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a manufacturer of genetic sequencing instruments and software. The contract is for the purchase of a MiSeq System, a benchtop DNA sequencing platform, for $95,931. The contract is a firm fixed price purchase order with no set-aside designation. Illumina has previously received other federal prime and subcontract awards from agencies like the National Institutes of Health (NIH),...
The Department of Health and Human Services Centers for Disease Control and Prevention (CDC) awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis, for ILLUMINA ISEQ 100 I1 REAGENT. The potential value of this contract is $9,991.97. This award is not associated with any larger contract vehicle and does not have a set-aside designation. Illumina has previously provided sequencing systems, reagents,...
This federal contract award to Illumina, Inc. is for the purchase of a NEXTSEQ 1000 SEQ SYSTEM, a genetic sequencing instrument, by the Centers for Disease Control and Prevention (CDC) in Pittsburgh, PA. The $159,600.00 firm fixed-price purchase order does not have a set-aside designation. Illumina is a manufacturer and provider of genetic and genomic analysis instruments and reagents, and has received previous prime contract awards from federal agencies like the NIH, USDA, and VA to support...

The Centers for Disease Control and Prevention (CDC) awarded a $95,931 firm-fixed-price purchase order to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, to provide a MiSeq next-generation DNA sequencing system. This sole-source award is intended to support the CDC's public health need for enhanced monitoring of HIV drug resistance in countries receiving PEPFAR (President's Emergency Plan for AIDS Relief) funding. Illumina was selected as the sole source due to its proprietary technology and ability to provide the necessary reagents compatible with the MiSeq instrument. No set-aside was used for this acquisition. Illumina has previously provided sequencing systems and related products to support research and diagnostics across various federal agencies.

Generated 4/2/25, 10:28 PM